![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RASSF3 |
Gene summary for RASSF3 |
![]() |
Gene information | Species | Human | Gene symbol | RASSF3 | Gene ID | 283349 |
Gene name | Ras association domain family member 3 | |
Gene Alias | RASSF5 | |
Cytomap | 12q14.2 | |
Gene Type | protein-coding | GO ID | GO:0006915 | UniProtAcc | Q86WH2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
283349 | RASSF3 | AEH-subject1 | Human | Endometrium | AEH | 2.01e-11 | 3.37e-01 | -0.3059 |
283349 | RASSF3 | AEH-subject2 | Human | Endometrium | AEH | 3.71e-04 | 2.83e-01 | -0.2525 |
283349 | RASSF3 | AEH-subject4 | Human | Endometrium | AEH | 1.52e-04 | 3.15e-01 | -0.2657 |
283349 | RASSF3 | EEC-subject1 | Human | Endometrium | EEC | 1.84e-02 | 2.67e-01 | -0.2682 |
283349 | RASSF3 | EEC-subject2 | Human | Endometrium | EEC | 3.61e-03 | 2.34e-01 | -0.2607 |
283349 | RASSF3 | EEC-subject3 | Human | Endometrium | EEC | 5.30e-06 | 3.33e-01 | -0.2525 |
283349 | RASSF3 | RNA-P17T-P17T-2 | Human | Lung | IAC | 7.27e-04 | 5.57e-01 | 0.3371 |
283349 | RASSF3 | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.33e-05 | 4.96e-01 | 0.343 |
283349 | RASSF3 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.02e-04 | 5.50e-01 | 0.3385 |
283349 | RASSF3 | RNA-P17T-P17T-8 | Human | Lung | IAC | 5.24e-04 | 4.49e-01 | 0.3329 |
Page: 1 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RASSF3 | SNV | Missense_Mutation | c.406N>A | p.Glu136Lys | p.E136K | Q86WH2 | protein_coding | deleterious(0.02) | benign(0.416) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
RASSF3 | SNV | Missense_Mutation | c.635A>G | p.Gln212Arg | p.Q212R | Q86WH2 | protein_coding | tolerated(0.51) | probably_damaging(0.986) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RASSF3 | SNV | Missense_Mutation | novel | c.331N>C | p.Asn111His | p.N111H | Q86WH2 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
RASSF3 | SNV | Missense_Mutation | c.618C>A | p.Asp206Glu | p.D206E | Q86WH2 | protein_coding | tolerated(0.79) | benign(0.01) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
RASSF3 | SNV | Missense_Mutation | novel | c.169N>G | p.Lys57Glu | p.K57E | Q86WH2 | protein_coding | deleterious(0) | possibly_damaging(0.84) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RASSF3 | SNV | Missense_Mutation | novel | c.433N>G | p.Lys145Glu | p.K145E | Q86WH2 | protein_coding | tolerated(0.52) | probably_damaging(0.999) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
RASSF3 | SNV | Missense_Mutation | c.662N>A | p.Thr221Lys | p.T221K | Q86WH2 | protein_coding | tolerated(0.22) | benign(0.006) | TCGA-AP-A0L9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
RASSF3 | SNV | Missense_Mutation | novel | c.261N>T | p.Met87Ile | p.M87I | Q86WH2 | protein_coding | tolerated(0.05) | benign(0.41) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RASSF3 | SNV | Missense_Mutation | novel | c.565G>A | p.Glu189Lys | p.E189K | Q86WH2 | protein_coding | deleterious(0) | possibly_damaging(0.687) | TCGA-CV-7242-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
RASSF3 | SNV | Missense_Mutation | rs776177789 | c.655N>T | p.Arg219Cys | p.R219C | Q86WH2 | protein_coding | deleterious(0.01) | benign(0.045) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |